The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letters to the EditorFull Access

Comment on Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25

To the Editor: We read with great interest the article by Sibley et al. (1), published in the February 2018 issue of the Journal, examining symptoms of attention deficit hyperactivity disorder (ADHD) longitudinally in a cohort without a baseline childhood diagnosis.

The authors identified cases of possible late-onset ADHD via screening and then used an iterative process to rule out nontrue cases. The overwhelming majority did not have true late-onset adult ADHD but had childhood symptoms persisting into adulthood, or they did not have ADHD (rather, they had cognitive impairment due to heavy substance use or other psychiatric morbidities).

These U.S. findings accord closely with our experience in U.K. adult ADHD clinics. We have not observed a single case of true adult-onset ADHD. The authors’ findings (1) support the need for specialist assessment by experienced ADHD clinicians. Screening instruments are blunt tools, potentially helpful for initial gate-keeping but not for confirming or refuting an ADHD diagnosis or for teasing apart nuanced differences from or overlap with other disorders.

Sibley and colleagues identified two adults with late-onset ADHD where the diagnosis may have been valid (i.e., there was an absence of childhood symptoms, and symptoms were not due to heavy substance use or other identified mental disorders). We wonder whether these uncommon cases may reflect organic pathology, such as cognitive dysfunction from thyroid disease or traumatic brain injury (diffuse axonal injury can give normal results on a brain scan) or other psychiatric disorders (e.g., impulse control disorders or gambling disorder, which are not typically screened for).

In the United Kingdom, there is a lack of National Health Service resourcing for adult ADHD. As Sibley et al. acknowledge, decades of research support ADHD as a chronic neurodevelopmental condition that often persists into adulthood (1). Recent DSM changes allow for the diagnosis of some high-functioning adult cases. The lack of resource provision in the United Kingdom is extremely unfortunate given ADHD’s high prevalence, coupled with the existence of clinically effective, cost-effective treatments. ADHD treatment may reduce criminality and driving accidents (2, 3). For those with ADHD treated appropriately, patients often report profound benefits for everyday functioning.

From the Department of Psychiatry, University of Cambridge, Cambridge, U.K.; the Adult ADHD Service, Cambridge and Peterborough NHS Foundation Trust, Cambridge, U.K.; and the Adult ADHD Service, Barnet Enfield Haringey NHS Mental Health Trust, London.
Address correspondence to Dr. Chamberlain ().

Dr. Chamberlain’s research has been funded by a clinical fellowship from the Wellcome Trust (reference 110049/Z/15/Z).

Dr. Chamberlain is a consultant for Cambridge Cognition and Shire. Dr. Müller has received speakers and consultancy honoraria and/or travel expenses from the British Association for Psychopharmacology, Eli Lilly, Flynn Pharma, Heptares, Medice, Shire, and the U.K. Adult ADHD Network.

References

1 Sibley MH, Rohde LA, Swanson JM, et al.: Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry 2018; 175:140–149LinkGoogle Scholar

2 Lichtenstein P, Halldner L, Zetterqvist J, et al.: Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006–2014Crossref, MedlineGoogle Scholar

3 Gobbo MA, Louzã MR: Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review. Eur Neuropsychopharmacol 2014; 24:1425–1443Crossref, MedlineGoogle Scholar